🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 13/10/2004 | 10,58 | 10,62 | 10,06 | 10,09 | -4,54% | 5,29% | 725.400 |
| 12/10/2004 | 10,81 | 10,94 | 10,53 | 10,57 | -4,26% | 3,79% | 484.200 |
| 11/10/2004 | 10,72 | 11,05 | 10,72 | 11,04 | +2,70% | 3,08% | 256.100 |
| 08/10/2004 | 11,04 | 11,15 | 10,70 | 10,75 | -2,71% | 4,08% | 460.600 |
| 07/10/2004 | 11,57 | 11,57 | 10,97 | 11,05 | -4,82% | 5,19% | 800.100 |
| 06/10/2004 | 11,09 | 11,73 | 10,77 | 11,61 | +4,41% | 8,66% | 1.151.600 |
| 05/10/2004 | 10,86 | 11,12 | 10,80 | 11,12 | +2,02% | 2,95% | 1.041.600 |
| 04/10/2004 | 10,50 | 10,91 | 10,35 | 10,90 | +2,93% | 5,33% | 767.700 |
| 01/10/2004 | 10,50 | 10,75 | 10,37 | 10,59 | +0,86% | 3,62% | 1.052.400 |
| 30/09/2004 | 10,04 | 10,60 | 9,91 | 10,50 | +5,21% | 6,87% | 823.300 |
| 29/09/2004 | 9,82 | 10,04 | 9,77 | 9,98 | +0,71% | 2,75% | 400.900 |
| 28/09/2004 | 9,78 | 9,93 | 9,66 | 9,91 | +2,69% | 2,76% | 492.100 |
| 27/09/2004 | 9,84 | 9,87 | 9,62 | 9,65 | -1,93% | 2,54% | 344.500 |
| 24/09/2004 | 10,04 | 10,10 | 9,84 | 9,84 | -1,89% | 2,59% | 231.600 |
| 23/09/2004 | 9,97 | 10,21 | 9,95 | 10,03 | -0,10% | 2,61% | 207.200 |
| 22/09/2004 | 10,48 | 10,53 | 9,99 | 10,04 | -4,92% | 5,15% | 499.100 |
| 21/09/2004 | 10,38 | 10,58 | 10,36 | 10,56 | +1,44% | 2,12% | 666.300 |
| 20/09/2004 | 10,89 | 10,89 | 10,20 | 10,41 | -4,32% | 6,34% | 659.300 |
| 17/09/2004 | 10,81 | 10,88 | 10,59 | 10,88 | +3,03% | 2,68% | 1.090.300 |
| 16/09/2004 | 10,56 | 10,70 | 10,47 | 10,56 | +0,00% | 2,18% | 568.800 |
| 15/09/2004 | 10,19 | 10,77 | 10,05 | 10,56 | +4,55% | 7,07% | 2.574.400 |
| 14/09/2004 | 10,72 | 10,75 | 9,90 | 10,10 | -6,48% | 7,93% | 2.947.400 |
| 13/09/2004 | 10,69 | 10,80 | 10,56 | 10,80 | +0,47% | 2,25% | 407.300 |
| 10/09/2004 | 10,43 | 10,75 | 10,25 | 10,75 | +3,27% | 4,79% | 246.900 |
| 09/09/2004 | 10,22 | 10,45 | 10,16 | 10,41 | +1,56% | 2,84% | 297.600 |
| 08/09/2004 | 10,37 | 10,49 | 10,05 | 10,25 | -0,87% | 4,24% | 560.500 |
| 07/09/2004 | 10,24 | 10,49 | 10,10 | 10,34 | +0,88% | 3,81% | 293.800 |
| 03/09/2004 | 10,27 | 10,48 | 10,12 | 10,25 | -0,87% | 3,51% | 341.500 |
| 02/09/2004 | 9,91 | 10,38 | 9,91 | 10,34 | +1,47% | 4,74% | 386.700 |
| 01/09/2004 | 9,78 | 10,27 | 9,51 | 10,19 | +4,73% | 7,77% | 598.500 |